Sustained clinical safety and efficacy of a biodegradable‐polymer coated sirolimus‐eluting stent in “real‐world” practice: Three‐year outcomes of the CREATE (multi‐center registry of EXCEL biodegradable polymer drug eluting stents) study
Authors:
- Yaling HanYHYaling Han
- Huiliang LiuHLHuiliang Liu
- The Multi‐Center Registry of EXCEL BiodegrAdable Polymer Drug EluTing Stents (CREATE) investigatorsTIThe Multi‐Center Registry of EXCEL BiodegrAdable Polymer Drug EluTing Stents (CREATE) investigators
- 30 November 2011
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 79 (2) , 211-216
Abstract
Background: The CREATE is a post‐marketing surveillance multicenter registry that demonstrated satisfactory angiographic and clinical (at 18 months) outcomes of a biodegradable polymer based sirolimus‐eluting stent (EXCEL, JW Medical System, Weihai, China) for the treatment of patients in routine clinical practice. Objectives: To evaluate the three‐year clinical safety and efficacy outcomes in patients enrolled in the CREATE study. Methods: A total of 2077 all comers have been enrolled in the CREATE study at 59 centers from four countries. Recommended antiplatelet regimen was clopidogrel and aspirin for six months followed by chronic aspirin therapy. The prespecified primary outcome was the rate of major adverse cardiac events (MACE) at 12, 18, and 36 months. Results: Clinical follow‐up was completed in 2025 (97.5%) patients at three years. The average duration of clopidogrel treatment was 199.8 ± 52.7 days and 80.5% of discharged patients discontinued clopidogrel at six months. The cumulative rate of MACE was 4.5% and the rate of stent thrombosis was 1.53% at three years. At six months to three years, prolonged clopidogrel therapy (>6 months) was not beneficial in reducing cumulative hazards of MACE (3.4% vs. 3.1%, log rank P = 0.725) or stent thrombosis (1.5% vs. 0.6%, log rank P = 0.053). Conclusions: This study demonstrates sustained three‐year clinical safety and efficacy of biodegradable polymer‐based sirolimus‐eluting stents when used with six months of dual antiplatelet therapy in a “real‐world” setting.Keywords
This publication has 28 references indexed in Scilit:
- TCT-36: LEADERS: 3-Year Follow-Up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable PolymerJACC, 2010
- Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting StentsNew England Journal of Medicine, 2010
- Final 5-Year Results of the TAXUS II TrialCirculation, 2009
- Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in “Real-World” PracticeJACC: Cardiovascular Interventions, 2009
- Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent PolymerJACC: Cardiovascular Interventions, 2009
- Long‐term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer‐coated sirolimus‐eluting stentsCatheterization and Cardiovascular Interventions, 2008
- Late Restenosis Following Sirolimus-Eluting Stent ImplantationThe American Journal of Cardiology, 2007
- Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery StentsJACC, 2007
- Vascular Healing 4 Years After the Implantation of Sirolimus-Eluting Stent in HumansCirculation, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003